Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483599 | 0.81 | KDM4E (0.54) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL26040850 | 0.77 | KDM4E (0.63) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14383869 | 0.76 | CNR2 (0.54) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21888553 | 0.74 | RAB9A (0.53) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19818735 | 0.73 | PTGS2 (0.46) | MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL23222980 | 0.72 | TDP1 (0.57) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21082270 | 0.72 | ALDH1A1 (0.44) | RAB9AMAPTNPC1ALDH1A1LMNA | |
| SCHEMBL2530349 | 0.71 | ALDH1A1 (0.50) | RAB9ANPC1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21889132 | 0.70 | CNR2 (0.59) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL312287 | 0.70 | KMT2A (0.92) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | RAB9A 396/4885MAPT 348/4885NPC1 1574/4885 |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | RAB9A 478/4885MAPT 4231/4885NPC1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.